Study of the Pathogenesis of Olfactory Disorders in COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

26 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-05-04

Study Completion Date

2020-10-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a case-control study to characterize the molecular and cellular anomalies of the olfactory epithelium of COVID-19 patients with isolated anosmia, by comparison with the olfactory epithelium of non-infected subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of the Evolution of Olfactory Disorders in Patients With Persistent Loss of Smell Following COVID-19

NCT05133596

SARS-CoV-2 Acute Respiratory Disease

COMPLETED NA

Anosmia and Covid-19

NCT05246059

Anosmia SARS CoV 2 Infection

COMPLETED NA

Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation

NCT06482138

Covid19 Olfactory Dysfunction

RECRUITING NA

Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity

NCT04361474

Budesonide Olfaction Disorders SARS-CoV-2 +1 more

COMPLETED PHASE3

Olfactory Training As a Treatment for Olfactory Dysfunction Post COVID-19

NCT05384561

Hyposmia COVID-19 Parosmia +2 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Olfactory and taste dysfunctions are common and early onset in COVID-19, especially in pauci symptomatic patients, and may be the main clinical manifestations of the infection. Olfactory dysfunction could result from infection of the olfactory system by SARS-CoV-2 or from inflammation induced by the virus. While the recent development of COVID-19 pulmonary lesion research has revealed a viral, inflammatory and vascular origin, factors that cause olfactory disorders in COVID-19 are just beginning.

Acute anosmia observed in some patients with COVID-19 could result from:

* the direct infection of olfactory sensory neurons or neural stem cells of the olfactory mucosa,
* an underlying inflammation of the olfactory mucosa, leading to possible neurodegeneration of olfactory sensory neurons, and neural stem cells of the olfactory mucosa, by analogy with the respiratory viruses responsible for chronic rhinosinusitis.

It is therefore necessary to conduct a virological, cellular, immunological and inflammatory study of the olfactory epithelium from COVID-19 patients with isolated anosmia to identify the origin of these olfactory disorders.

This study is a case-control study to characterize the molecular and cellular anomalies of the olfactory epithelium of COVID-19 patients with isolated anosmia, by comparison with the olfactory epithelium of non-infected subjects.

Following measures will be performed at inclusion :

* Taste and olfactory function evaluation by a self-questionnaire taste and smell survey (TTS) and a visual analogue scale (VAS)
* Nasal swab sampling for collection of epithelium cells and olfactory mucus.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronavirus Infection Severe Acute Respiratory Syndrome Sars-CoV2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COVID-19 patients

Subject consulting in the Lariboisière hospital (Paris) in the context of the COVID-19 screening care for a suspected SARS-CoV-2 infection

Nasal swab

Intervention Type OTHER

Nasal swab

Taste and olfactory function evaluation

Intervention Type OTHER

Taste and olfactory function evaluation

Control subjects

Subject consulting in the ear, nose and throat department at the Lariboisière hospital (Paris) with no biologically confirmed COVID-19 or suspected COVID-19 in the past 8 weeks, and no symptoms suggestive of COVID-19 or another respiratory disease and therefore no recent anosmia or ageusia

Nasal swab

Intervention Type OTHER

Nasal swab

Taste and olfactory function evaluation

Intervention Type OTHER

Taste and olfactory function evaluation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nasal swab

Intervention Type OTHER

Taste and olfactory function evaluation

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

COVID-19 patients

* Age \> 18 years
* Subject consulting in the context of the COVID-19 screening care for a suspected SARS-CoV-2 infection

Controls

* Age \> 18 years
* Subject consulting in the ear, nose and throat department with no biologically confirmed COVID-19 or suspected COVID-19 in the past 8 weeks, and no symptoms suggestive of COVID-19 or another respiratory disease and therefore no recent anosmia or ageusia